PACB logo

PACB

Profile

Full Name

Pacific Biosciences of California, Inc.

Ticker Symbol

PACB

Exchange

NASDAQ

Sector

Healthcare

Industry

Medical Devices

Country

United States

IPO

October 27, 2010

Indexes

Not included

Website

http://www.pacb.com

Employees

575

Key Details

Price

$1.17(-2.50%)

Market cap

$348.49M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$154.01M(-23.19% YoY)

Annual EPS

-$1.59(-31.40% YoY)

PE ratio

-

Next earnings date

May 8, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$1.17
PACB price is $1.17

30-Day Relative Volume

0.44
PACB 30-day relative volume is 0.44

Price Performance

Price Most recent change

-2.5%
PACB price was down -2.5% on Apr 17, 2025

Price YTD change

-36.07%
PACB price is down -36.07% since January 1st

Price 1-year change

-16.43%
PACB price is down -16.43% year-on-year

Price 3-year change

-84.48%
PACB price is down -84.48% over the past 3 years

Price Range

Price All-time high

$53.69
PACB price is currently -97.82% below its historical high of $53.69

Price 3-year low

$1.08
PACB price is currently +8.33% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$348.49M
PACB market capitalization is $348.49 million

Market cap 3-year change

-79.4%
PACB market capitalization is down -79.4% over the past 3 years

Market cap All-time high

$9.88B
PACB market capitalization is currently -96.47% below its historical high of $9.88 billion

Market cap sector rank

64.53%
PACB market capitalization is higher than 64.53% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+9.39%
PACB shares outstanding is up +9.39% year-on-year

Shares Outstanding 3-Year Change

+32.77%
PACB shares outstanding is up +32.77% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.85
PACB beta is 1.85

200-day SMA

$1.69
PACB price is currently -30.65% below its 200-day simple moving average

50-day SMA

$1.37
PACB price is currently -14.39% below its 50-day simple moving average

RSI

42.81
PACB 14-day relative strength index is 42.81

Volume

0.44
PACB 30-day relative volume is 0.44

ATR

$0.12
PACB average true range is $0.12

10-day Historical Volatility

136.58%
PACB 10-day historical volatility is 136.58%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$154.01M
PACB annual revenue is $154.01 million

Revenue Analysts estimate

$160.20M
PACB annual revenue is currently -3.86% lower than the consensus analysts' forecast

Revenue 1-year change

-23.19%
PACB annual revenue is down -23.19% year-on-year

Revenue Sector rank

60.54%
PACB annual revenue is higher than 60.54% of companies in Healthcare sector

EPS

EPS

-$1.59
PACB annual earnings per share is -$1.59

EPS Analysts estimate

-$0.71
PACB annual earnings per share is currently +123.31% higher than the consensus analysts' forecast

EPS 1-year change

-31.4%
PACB annual earnings per share is down -31.4% year-on-year

EPS Sector rank

43.99%
PACB annual earnings per share is higher than 43.99% of companies in Healthcare sector

Profit

Gross profit

$37.28M
PACB annual gross profit is $37.28 million

Gross margin

24.21%
PACB annual gross profit margin is 24.21%

Operating profit

-$290.66M
PACB annual operating income is -$290.66 million

Operating margin

-188.73%
PACB annual operating profit margin is -188.73%

Net income

-$309.85M
PACB annual net profit is -$309.85 million

Net margin

-200.40%
PACB annual net profit margin is -200.40%

Expenses

Total expenses

$444.68M
PACB annual total expenses is $444.68 million

Operating expenses

$327.94M
PACB annual total operating expenses is $327.94 million

Cost of goods sold

$116.73M
PACB annual cost of goods sold is $116.73 million

Selling, general & administrative expenses

$175.02M
PACB annual SGA is $175.02 million

Depreciation and amortization

$53.35M
PACB annual depreciation & amortization is $53.35 million

Interest expense

$13.41M
PACB annual interest expense is $13.41 million

Income tax

$316.00K
PACB annual income tax is $316.00 thousand

EBIT & EBITDA

EBIT

-$294.92M
PACB annual earnings before interest & taxes is -$294.92 million

EBITDA

-$276.92M
PACB annual EBITDA is -$276.92 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$1.26B
PACB annual total assets is $1.26 billion

Non current assets

$764.77M
PACB annual long term assets is $764.77 million

Current assets

$495.68M
PACB annual total current assets is $495.68 million

Cash and cash equivalents

$55.37M
PACB annual cash & cash equivalents is $55.37 million

Accounts receivable

$27.52M
PACB annual accounts receivable is $27.52 million

Inventory

$58.76M
PACB annual inventory is $58.76 million

Liabilities

Total liabilities

$753.85M
PACB annual total liabilities is $753.85 million

Long term liabilities

$687.55M
PACB annual total long term liabilities is $687.55 million

Current liabilities

$66.30M
PACB annual total current liabilities is $66.30 million

Accounts payable

$16.59M
PACB annual accounts payable is $16.59 million

Debt

Total debt

$672.43M
PACB annual total debt is $672.43 million

Total debt 1-year change

-28%
PACB annual total debt is down -28% year-on-year

Long term debt

$662.41M
PACB annual long term debt is $662.41 million

Short term debt

$10.03M
PACB annual short term debt is $10.03 million

Equity & Capital

Shareholders equity

$506.59M
PACB annual stockholders equity is $506.59 million

Book value

$506.59M
PACB annual book value is $506.59 million

Retained earnings

-$2.15B
PACB annual retained earnings is -$2.15 billion

Working capital

$429.38M
PACB annual working capital is $429.38 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$206.06M
PACB annual cash flow from operations is -$206.06 million

Cash from operations 1-year change

+20.49%
PACB annual cash flow from operations is up +20.49% year-on-year

Cash from investing

$124.00M
PACB annual cash flow from investing activities is $124.00 million

Cash from investing 1-year change

+2593.4%
PACB annual cash flow from investing activities is up +2593.4% year-on-year

Cash from financing

-$42.99M
PACB annual cash flow from financing activities is -$42.99 million

Cash from financing 1-year change

-139.48%
PACB annual cash flow from financing activities is down -139.48% year-on-year

CAPEX

CAPEX

$6.19M
PACB annual capital expenditures is $6.19 million

CAPEX 1-year change

-30.02%
PACB annual capital expenditures is down -30.02% year-on-year

Free Cash Flow

Free cash flow

-$212.25M
PACB annual free cash flow is -$212.25 million

Free cash flow 1-year change

+20.81%
PACB annual free cash flow is up +20.81% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

24.21%
PACB annual gross profit margin is 24.21%

Operating margin

-188.73%
PACB annual operating profit margin is -188.73%

Net margin

-200.40%
PACB annual net profit margin is -200.40%

ROA & ROE

ROA

-20.61%
PACB annual return on assets is -20.61%

ROE

-51.30%
PACB annual return on equity is -51.30%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
PACB price to earnings ratio value is unknown

PE ratio Sector rank

-
PACB price to earnings ratio is unknown

PB Ratio

PB ratio

0.69
PACB price to book ratio is 0.69

PB ratio Sector rank

36.44%
PACB price to book ratio is higher than 36.44% of companies in Healthcare sector

PS Ratio

PS ratio

2.26
PACB price to sales ratio is 2.26

PS ratio Sector rank

45.44%
PACB price to sales ratio is higher than 45.44% of companies in Healthcare sector

Enterprise value

Enterprise value

$965.55M
PACB enterprise value is $965.55 million

Enterprise value Sector rank

75.37%
PACB enterprise value is higher than 75.37% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-3.90
PACB EV/EBITDA is -3.90

EV/EBITDA Sector rank

22.11%
PACB EV/EBITDA is higher than 22.11% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

7.48
PACB annual current ratio is 7.48

Quick ratio

6.59
PACB annual quick ratio is 6.59

Leverage

Debt to equity

1.28
PACB annual debt to equity ratio is 1.28

Interest coverage ratio

-21.99
PACB annual interest coverage ratio is -21.99

Risk & Stability

Piotroski F-Score

3
PACB piotroski f-score is 3

Altman Z-Score

-2.35
PACB altman z-score is -2.35

Analyst ratings

Recent major analysts updates

Apr 10, 25 Canaccord Genuity
Buy
Mar 25, 25 Scotiabank
Sector Outperform
Feb 20, 25 Piper Sandler
Neutral
Feb 18, 25 Stephens & Co.
Overweight
Feb 18, 25 Goldman Sachs
Neutral
Feb 14, 25 Stephens & Co.
Overweight
Jan 23, 25 Goldman Sachs
Neutral
Nov 11, 24 UBS
Neutral
Nov 11, 24 Scotiabank
Sector Outperform
Nov 11, 24 Piper Sandler
Neutral

Institutional Ownership

Similar stocks

ALT logo
Altimmune (ALT)
NPCE logo
NeuroPace (NPCE)
Oruka Therapeutics (ORKA)
AMLX logo
Amylyx Pharmaceuticals (AMLX)
ORIC logo
ORIC Pharmaceuticals (ORIC)
CKPT logo
Checkpoint Therapeutics (CKPT)
CLPT logo
ClearPoint Neuro (CLPT)
Maze Therapeutics (MAZE)
TBRG logo
TruBridge (TBRG)
  • What is the ticker symbol for Pacific Biosciences of California?
  • Does Pacific Biosciences of California pay dividends?
  • What sector is Pacific Biosciences of California in?
  • What industry is Pacific Biosciences of California in?
  • What country is Pacific Biosciences of California based in?
  • When did Pacific Biosciences of California go public?
  • Is Pacific Biosciences of California in the S&P 500?
  • Is Pacific Biosciences of California in the NASDAQ 100?
  • Is Pacific Biosciences of California in the Dow Jones?
  • When was Pacific Biosciences of California's last earnings report?
  • When does Pacific Biosciences of California report earnings?
  • Should I buy Pacific Biosciences of California stock now?

What is the ticker symbol for Pacific Biosciences of California?

The ticker symbol for Pacific Biosciences of California is NASDAQ:PACB

Does Pacific Biosciences of California pay dividends?

No, Pacific Biosciences of California does not pay dividends

What sector is Pacific Biosciences of California in?

Pacific Biosciences of California is in the Healthcare sector

What industry is Pacific Biosciences of California in?

Pacific Biosciences of California is in the Medical Devices industry

What country is Pacific Biosciences of California based in?

Pacific Biosciences of California is headquartered in United States

When did Pacific Biosciences of California go public?

Pacific Biosciences of California's initial public offering (IPO) was on October 27, 2010

Is Pacific Biosciences of California in the S&P 500?

No, Pacific Biosciences of California is not included in the S&P 500 index

Is Pacific Biosciences of California in the NASDAQ 100?

No, Pacific Biosciences of California is not included in the NASDAQ 100 index

Is Pacific Biosciences of California in the Dow Jones?

No, Pacific Biosciences of California is not included in the Dow Jones index

When was Pacific Biosciences of California's last earnings report?

Pacific Biosciences of California's most recent earnings report was on Feb 13, 2025

When does Pacific Biosciences of California report earnings?

The next expected earnings date for Pacific Biosciences of California is May 8, 2025

Should I buy Pacific Biosciences of California stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page